Martin J Bergman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6677589/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety of jakinibs: lessons from ORAL Surveillance. Rheumatology, 2022, 61, 4223-4225.	0.9	1
2	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naÃ ⁻ ve Patients With Psoriatic Arthritis. Journal of Rheumatology, 2022, 49, 694-699.	1.0	4
3	Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits. Arthritis Care and Research, 2021, 73, 1809-1814.	1.5	22
4	Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology, 2021, 60, 3209-3221.	0.9	14
5	Dataâ€Ðriven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. Arthritis Care and Research, 2021, 73, 471-480.	1.5	12
6	Comment on: †It can't be zero!' Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study. Rheumatology, 2021, 60, e28-e29.	0.9	3
7	Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. Rheumatology and Therapy, 2021, 8, 109-118.	1.1	25
8	Upadacitinib improves patient-reported outcomes <i>vs</i> placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology, 2021, 60, 5583-5594.	0.9	17
9	Healthcare Costs of Not Achieving Remission in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study. Advances in Therapy, 2021, 38, 2558-2570.	1.3	6
10	Use of Precision Medicine to Guide Treatment of Patients With Rheumatoid Arthritis: Comment on the Article by Tao et al. Arthritis and Rheumatology, 2021, 73, 1567-1569.	2.9	0
11	Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis. Advances in Therapy, 2021, 38, 5302-5316.	1.3	5
12	Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Advances in Therapy, 2021, 38, 5649-5661.	1.3	4
13	Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1734-1742.	0.5	2
14	Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Rheumatology, 2020, 59, 2090-2098.	0.9	10
15	Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. Rheumatology and Therapy, 2020, 7, 775-792.	1.1	19
16	High Burden of Burnout on Rheumatology Practitioners. Journal of Rheumatology, 2020, 47, 1831-1834.	1.0	15
17	Reply. Arthritis Care and Research, 2020, 72, 736-738.	1.5	0
18	Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada. Rheumatology International, 2019, 39, 1621-1630.	1.5	5

Martin J Bergman

#	Article	IF	CITATIONS
19	2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care and Research, 2019, 71, 1540-1555.	1.5	157
20	FRI0137â€UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRI AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM SELECT-COMPARE. , 2019, , .	TIS	2
21	THU0448â€DISEASE BURDEN IN OSTEOARTHRITIS (OA) IS SIMILAR TO RHEUMATOID ARTHRITIS (RA) FROM TH PATIENT'S PERSPECTIVE, SLIGHTLY HIGHER IN RA AT PRESENTATION, SIMILAR ONE YEAR LATER, AND SLIGHTL HIGHER IN OA TWO YEARS LATER AT ONE PRIVATE PRACTICE SETTING. , 2019, , .		0
22	Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Clinical Rheumatology, 2018, 37, 2043-2053.	1.0	9
23	Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis. Rheumatology, 2018, 57, 419-428.	0.9	11
24	Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial. Clinical Rheumatology, 2017, 36, 1357-1367.	1.0	2
25	Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. Rheumatology International, 2017, 37, 1111-1123.	1.5	10
26	Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab. Arthritis Care and Research, 2017, 69, 609-615.	1.5	11
27	Methods for Developing the American College of Rheumatology's Electronic Clinical Quality Measures. Arthritis Care and Research, 2016, 68, 1402-1409.	1.5	13
28	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.5	1,114
29	Three-Quarters of Persons in the US Population Reporting a Clinical Diagnosis of Fibromyalgia Do Not Satisfy Fibromyalgia Criteria: The 2012 National Health Interview Survey. PLoS ONE, 2016, 11, e0157235.	1.1	66
30	Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 2046-2054.	1.0	58
31	The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. PLoS ONE, 2015, 10, e0138024.	1.1	202
32	Is Fatigue an Inflammatory Variable in Rheumatoid Arthritis (RA)? Analyses of Fatigue in RA, Osteoarthritis, and Fibromyalgia. Journal of Rheumatology, 2009, 36, 2788-2794.	1.0	76